Search

Displaying results 421 - 430 of 4233 in total
  1. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    Linvoseltamab (INN), marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma … This mechanism results in the targeted release of cytokines such as IL-2, IL-6, and IFN-gamma, promoting the selective lysis of BCMA-expressing cells and offering a novel immunotherapeutic approach for

  2. Drug

    Lenalidomide

    go.drugbank.com/drugs/DB00480
    ApprovedInvestigational

    [A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that … Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties.

  3. Drug

    Pemigatinib

    go.drugbank.com/drugs/DB15102
    ApprovedInvestigational

    [A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast … Pemigatinib is marketed under the brand name Pemazyre, and it is available as oral tablets.[L13050]

  4. Drug

    Acrivastine

    go.drugbank.com/drugs/DB09488
    Approved

    As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension … Acrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D.

  5. Drug

    Ivosidenib

    go.drugbank.com/drugs/DB14568
    ApprovedInvestigational

    [A248745] It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma

  6. Drug

    Imipenem

    go.drugbank.com/drugs/DB01598
    ApprovedInvestigational

    Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co.[L7628]

  7. Drug

    Proparacaine

    go.drugbank.com/drugs/DB00807
    ApprovedVet approved

    It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

  8. Drug

    Vigabatrin

    go.drugbank.com/drugs/DB01080
    ApprovedInvestigational

    Although administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active. … [A202037] It was first introduced as an antiepileptic agent in the United Kingdom in 1989 and was used extensively until 1997, when an association with vision loss became apparent.

  9. Drug

    Levothyroxine

    go.drugbank.com/drugs/DB00451
    ApprovedInvestigational

    [A179935] As a result, many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status. … [F4633] Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient

  10. Drug

    Umeclidinium

    go.drugbank.com/drugs/DB09076
    ApprovedInvestigational

    [A7718,A7714] Umeclidinium was approved by the FDA in April 2014 under the brand name Incruse Ellipta as a standalone product. … Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD).